Matching articles for "Nimerix"

Penmenvy — A Second Pentavalent Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • April 14, 2025;  (Issue 1726)
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years...
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):57-9 | Show Full IntroductionHide Full Introduction